174 related articles for article (PubMed ID: 27196064)
1. The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.
Ford NF
J Clin Pharmacol; 2016 Dec; 56(12):1474-1483. PubMed ID: 27196064
[TBL] [Abstract][Full Text] [Related]
2. Clopidogrel, CYP2C19, and a Black Box.
Ford NF; Taubert D
J Clin Pharmacol; 2013 Mar; 53(3):241-8. PubMed ID: 23381692
[TBL] [Abstract][Full Text] [Related]
3. Grapefruit juice inhibits the metabolic activation of clopidogrel.
Holmberg MT; Tornio A; Neuvonen M; Neuvonen PJ; Backman JT; Niemi M
Clin Pharmacol Ther; 2014 Mar; 95(3):307-13. PubMed ID: 24067745
[TBL] [Abstract][Full Text] [Related]
4. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
Zahno A; Brecht K; Bodmer M; Bur D; Tsakiris DA; Krähenbühl S
Br J Pharmacol; 2010 Sep; 161(2):393-404. PubMed ID: 20735423
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
[TBL] [Abstract][Full Text] [Related]
6. Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.
Zhang H; Ragueneau-Majlessi I; Levy RH
Drug Metab Lett; 2009 Dec; 3(4):287-9. PubMed ID: 19995331
[TBL] [Abstract][Full Text] [Related]
7. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4.
Ohbuchi M; Noguchi K; Kawamura A; Usui T
Xenobiotica; 2012 Jul; 42(7):633-40. PubMed ID: 22313038
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
[TBL] [Abstract][Full Text] [Related]
9. Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial.
Hirsh-Rokach B; Spectre G; Shai E; Lotan A; Ritter A; Al-Aieshy F; Malmström RE; Varon D; Alcalai R
Pharmacotherapy; 2015 Feb; 35(2):140-7. PubMed ID: 25689244
[TBL] [Abstract][Full Text] [Related]
10. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
Farid NA; Kurihara A; Wrighton SA
J Clin Pharmacol; 2010 Feb; 50(2):126-42. PubMed ID: 19948947
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?
Knauer MJ; Diamandis EP; Hulot JS; Kim RB; So DY
Clin Chem; 2015 Oct; 61(10):1235-40. PubMed ID: 26272232
[No Abstract] [Full Text] [Related]
14. Human Liver Cytochrome P450 Enzymes and Microsomal Thiol Methyltransferase Are Involved in the Stereoselective Formation and Methylation of the Pharmacologically Active Metabolite of Clopidogrel.
Liu C; Chen Z; Zhong K; Li L; Zhu W; Chen X; Zhong D
Drug Metab Dispos; 2015 Oct; 43(10):1632-41. PubMed ID: 26220948
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
[TBL] [Abstract][Full Text] [Related]
16. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
Liu Q; Dang DS; Chen YF; Yan M; Shi GB; Zhao QC
Genet Test Mol Biomarkers; 2012 Nov; 16(11):1293-7. PubMed ID: 23046071
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it means.
Hariharan S; Southworth MR; Madabushi R
J Clin Pharmacol; 2014 Aug; 54(8):884-8. PubMed ID: 25044100
[No Abstract] [Full Text] [Related]
18. Cytochrome p-450 polymorphisms and response to clopidogrel.
Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS
N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel pathway.
Sangkuhl K; Klein TE; Altman RB
Pharmacogenet Genomics; 2010 Jul; 20(7):463-5. PubMed ID: 20440227
[No Abstract] [Full Text] [Related]
20. [Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes].
Lu FM; Tong ZL; Mao YM; Wu DY; Xu J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Aug; 29(4):478-81. PubMed ID: 22875511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
